Insider Transactions in Q2 2023 at Edwards Lifesciences Corp (EW)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,255
-27.37%
|
$674,715
$93.27 P/Share
|
|
Jun 30
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,255
+21.49%
|
$261,180
$36.75 P/Share
|
|
Jun 14
2023
|
Larry L Wood Global President TAVR & Surg |
SELL
Open market or private sale
|
Direct |
8,660
-1.96%
|
$779,400
$90.29 P/Share
|
|
Jun 14
2023
|
Larry L Wood Global President TAVR & Surg |
BUY
Exercise of conversion of derivative security
|
Direct |
8,660
+3.75%
|
$389,700
$45.28 P/Share
|
|
Jun 14
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
3,500
-8.14%
|
$311,500
$89.77 P/Share
|
|
Jun 14
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+7.53%
|
$126,000
$36.75 P/Share
|
|
Jun 13
2023
|
Catherine M. Szyman CVP, Critical Care |
SELL
Open market or private sale
|
Direct |
5,000
-12.48%
|
$425,000
$85.81 P/Share
|
|
Jun 13
2023
|
Catherine M. Szyman CVP, Critical Care |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.1%
|
$180,000
$36.75 P/Share
|
|
Jun 01
2023
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
29,350
-9.09%
|
$2,465,400
$84.36 P/Share
|
|
Jun 01
2023
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,350
+20.25%
|
$1,056,600
$36.75 P/Share
|
|
May 24
2023
|
Larry L Wood Global President TAVR & Surg |
SELL
Open market or private sale
|
Direct |
6,421
-2.92%
|
$539,364
$84.23 P/Share
|
|
May 24
2023
|
Larry L Wood Global President TAVR & Surg |
BUY
Exercise of conversion of derivative security
|
Direct |
6,421
+2.83%
|
$288,945
$45.28 P/Share
|
|
May 17
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Bona fide gift
|
Indirect |
8,496
+3.09%
|
-
|
|
May 17
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
8,496
-30.62%
|
-
|
|
May 12
2023
|
Nicholas J Valeriani Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+3.91%
|
-
|
|
May 12
2023
|
Michael A Mussallem Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,485
+4.95%
|
-
|
|
May 12
2023
|
Heisz Leslie Stone Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+8.47%
|
-
|
|
May 12
2023
|
Kieran Gallahue Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,701
+34.76%
|
-
|
|
May 12
2023
|
Paul A Laviolette Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+26.64%
|
-
|
|
May 12
2023
|
Steven R Loranger Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,701
+3.19%
|
-
|
|
May 12
2023
|
Martha H. Marsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+8.08%
|
-
|
|
May 12
2023
|
Ramona Sequeira Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+35.45%
|
-
|
|
May 11
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,450
+25.41%
|
-
|
|
May 11
2023
|
Daveen Chopra CVP, TMTT |
BUY
Grant, award, or other acquisition
|
Direct |
6,475
+20.28%
|
-
|
|
May 11
2023
|
Catherine M. Szyman CVP, Critical Care |
BUY
Grant, award, or other acquisition
|
Direct |
6,525
+15.69%
|
-
|
|
May 11
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Grant, award, or other acquisition
|
Direct |
6,425
+13.99%
|
-
|
|
May 11
2023
|
Bernard J Zovighian CEO |
BUY
Grant, award, or other acquisition
|
Direct |
22,525
+33.58%
|
-
|
|
May 11
2023
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
BUY
Grant, award, or other acquisition
|
Direct |
1,575
+0.9%
|
-
|
|
May 11
2023
|
Larry L Wood Global President TAVR & Surg |
BUY
Grant, award, or other acquisition
|
Direct |
7,775
+3.51%
|
-
|
|
May 11
2023
|
Robert W.A. Sellers SVP, Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
1,800
+12.13%
|
-
|
|
May 10
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
2,500
-7.03%
|
$222,500
$89.22 P/Share
|
|
May 10
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+6.57%
|
$90,000
$36.75 P/Share
|
|
May 10
2023
|
Michael A Mussallem Director |
BUY
Bona fide gift
|
Indirect |
9,500
+0.26%
|
-
|
|
May 10
2023
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
19,875
-9.96%
|
$1,749,000
$88.62 P/Share
|
|
May 10
2023
|
Michael A Mussallem Director |
SELL
Bona fide gift
|
Direct |
9,500
-9.04%
|
-
|
|
May 10
2023
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,375
+20.91%
|
$1,028,125
$35.2 P/Share
|
|
May 10
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
80,700
-47.28%
|
$7,101,600
$88.79 P/Share
|
|
May 10
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
80,700
+44.91%
|
$2,824,500
$35.2 P/Share
|
|
May 09
2023
|
Catherine M. Szyman CVP, Critical Care |
SELL
Open market or private sale
|
Direct |
75,600
-72.6%
|
$6,652,800
$88.94 P/Share
|
|
May 09
2023
|
Catherine M. Szyman CVP, Critical Care |
BUY
Exercise of conversion of derivative security
|
Direct |
75,600
+42.06%
|
$2,646,000
$35.2 P/Share
|
|
May 09
2023
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Open market or private sale
|
Direct |
6,640
-3.72%
|
$584,320
$88.68 P/Share
|
|
May 09
2023
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
BUY
Exercise of conversion of derivative security
|
Direct |
6,640
+3.58%
|
$232,400
$35.2 P/Share
|
|
May 08
2023
|
Bernard J Zovighian CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,433
-6.11%
|
$126,104
$88.74 P/Share
|
|
May 08
2023
|
Robert W.A. Sellers SVP, Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
161
-1.41%
|
$14,168
$88.74 P/Share
|
|
May 08
2023
|
Catherine M. Szyman CVP, Critical Care |
SELL
Payment of exercise price or tax liability
|
Direct |
1,376
-4.6%
|
$121,088
$88.74 P/Share
|
|
May 08
2023
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
104
-0.06%
|
$9,152
$88.74 P/Share
|
|
May 08
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,674
-8.38%
|
$147,312
$88.74 P/Share
|
|
May 08
2023
|
Daveen Chopra CVP, TMTT |
SELL
Payment of exercise price or tax liability
|
Direct |
967
-4.85%
|
$85,096
$88.74 P/Share
|
|
May 08
2023
|
Larry L Wood Global President TAVR & Surg |
SELL
Payment of exercise price or tax liability
|
Direct |
1,472
-0.71%
|
$129,536
$88.74 P/Share
|
|
May 08
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Payment of exercise price or tax liability
|
Direct |
1,399
-2.41%
|
$123,112
$88.74 P/Share
|